Related Experiment Video

Updated: Jul 20, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Integrating genomics as clinical biomarkers in pediatric pulmonology

Erick Forno1

  • 1Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children, Indianapolis, Indiana, USA.

Pediatric Pulmonology
|October 3, 2024
PubMed

Insights

Omics technologies, like epigenomics and transcriptomics, show promise for identifying new biomarkers in pediatric respiratory diseases. These advancements could lead to better clinical tools for conditions such as asthma and cystic fibrosis.

Area of Science:

  • Pediatric Pulmonology
  • Genomics and Molecular Biology

Background:

  • Respiratory diseases arise from intricate genetic and environmental interactions.
  • Understanding these interactions is crucial for developing effective treatments.

Purpose of the Study:

  • To review the potential of "omics" technologies in pediatric pulmonary medicine.
  • To highlight epigenomics and transcriptomics for clinical biomarker development.
  • To use asthma and cystic fibrosis as illustrative examples.

Main Methods:

  • Review of current literature on "omics" applications in pediatric respiratory diseases.
  • Focus on epigenomic and transcriptomic data analysis.
  • Case study approach using asthma and cystic fibrosis.

Main Results:

  • "Omics" data offer insights into disease mechanisms.
  • Epigenomics and transcriptomics show potential for identifying novel biomarkers.
  • Biomarkers could aid in early diagnosis and personalized treatment.

Conclusions:

  • "Omics" technologies, particularly epigenomics and transcriptomics, are valuable tools.
  • These "omics" approaches hold significant promise for clinical biomarker discovery in pediatric pulmonary medicine.
  • Further research is warranted to translate these findings into clinical practice.

Keywords:
asthmacystic fibrosisgenomicstranscriptomics

More Related Videos

Breath Collection from Children for Disease Biomarker Discovery06:09

Breath Collection from Children for Disease Biomarker Discovery

Published on: February 14, 2019

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...